Inloggad som:
Relativity-127
Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.
Relativity-127
A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixeddose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma
A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixeddose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma
PLACEHOLDER
Randomisering mellan Subcutaneous Nivolumab + Relatlimab versus Intravenös Nivolumab + Relatlimab till patienter med tidigare obehandlad metastaserad malignt melanom
Mer information om studien för vårdgivare
Studien ändrades senast av: studyjohanna (2024-08-26)